ITRMF (Iterum Therapeutics) Total Operating Expense: $20.07 Mil (TTM As of Sep. 2025)


What is Iterum Therapeutics Total Operating Expense?

Iterum Therapeutics ITRMF +18.86% Total Operating Expense is $20.07 Mil as of Sep. 2025. The stock has 4 warning signs investors should review.

Iterum Therapeutics's Total Operating Expense for the three months ended in Sep. 2025 was $8.10 Mil. Iterum Therapeutics's Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 was $20.07 Mil.

Iterum Therapeutics Total Operating Expense Related Terms

Iterum Therapeutics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Iterum Therapeutics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Iterum Therapeutics Total Operating Expense Chart

Iterum Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only 32.13 24.54 30.38 47.47 18.44

Iterum Therapeutics Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.89 3.42 3.37 5.18 8.10

Iterum Therapeutics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $20.07 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $20.07 Mil mean?
Iterum Therapeutics (ITRMF) has a Total Operating Expense of $20.07 Mil as of Sep. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Iterum Therapeutics and its competitors.
Is Iterum Therapeutics' Total Operating Expense too high?
Iterum Therapeutics' current Total Operating Expense is $20.07 Mil.
How does Iterum Therapeutics' Total Operating Expense compare to ENSC and PPCB?
Iterum Therapeutics' Total Operating Expense of $20.07 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Iterum Therapeutics and its competitors. Iterum Therapeutics's current Total Operating Expense is $20.07 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Iterum Therapeutics stock overvalued right now?
Iterum Therapeutics (ITRMF) has a current Total Operating Expense of $20.07 Mil. The current Total Operating Expense is $20.07 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Iterum Therapeutics (ITRMF), the current Total Operating Expense is $20.07 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Iterum Therapeutics Business Description

Address 3 Dublin Landings, North Wall Quay, Dublin 1, Dublin, IRL, D01 C4E0
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.